Because breast cancer is everywhere, **SO ARE WE.**

At Susan G. Komen for the Cure®, we are committed to ENDING breast cancer forever by ENERGIZING SCIENCE to find the cures and ensuring QUALITY CARE for all people, everywhere.

**INVESTIGATOR-INITIATED RESEARCH GRANTS**

2011-2012 REQUEST FOR APPLICATIONS

Research Focus Areas:

- **Prevention/Early Detection:** Prognostic factors of premalignant lesions, including atypical hyperplasia and carcinoma in situ
- **Novel Therapeutics and Resistance:** Targeted therapies for triple negative breast cancer
- **Biology of Breast Cancer:** Implications for host and/or tumor genetics
- **Disparities in Breast Cancer Outcomes:** All issues relevant to disparities as defined in this RFA

Susan G. Komen for the Cure
5005 LBJ Freeway, Suite 250
Dallas, Texas 75244
Research Programs Help Desk: 1-866-921-9678
Email: helpdesk@komengrantsaccess.org
Website: www.komen.org
**KEY DATES**

- **Application System Opens**: July 1, 2011
- **Pre-Application Due**: August 10, 2011, by 8 p.m., ET
- **Pre-Application Decision**: October 18, 2011
- **Full Application Due**: December 15, 2011, by 8 p.m., ET
- **Award Notification**: March 31, 2012

**KOMEN RESEARCH PROGRAM**

Susan G. Komen for the Cure’s Research Programs play a critical role in energizing science to find the cures by funding the discoveries, individuals, and resources essential to ending breast cancer. The Programs support research and training through many different types of grants and awards, each designed to meet specific objectives and optimize outcomes. The 2011-2012 Request for Applications (RFAs) continues Komen’s strategic focus on reducing breast cancer incidence and mortality within the decade.

**INVESTIGATOR-INITIATED RESEARCH GRANTS**

Investigator-Initiated Research (IIR) Grants seek to stimulate exploration of new ideas and novel approaches in breast cancer research and clinical practice that have significant potential to lead to reductions in breast cancer incidence and/or mortality within the next decade.

**2011-2012 Investigator-Initiated Research Focus Areas**

Applications for FY12 Investigator Initiated Research Grants must focus on one of the following topics. Applications addressing topics other than those described below will be administratively withdrawn from consideration, and will not be reviewed or scored.

- **Prevention/Early Detection – Premalignant Lesions (including atypical hyperplasia and carcinoma in situ)**
  Research seeking to characterize premalignant lesions to identify or treat women at high risk for developing invasive breast cancer.

- **Novel Therapeutics and/or Resistance – Targeted Therapies for Triple Negative Breast Cancer**
  Research seeking to a) identify, validate, and/or test new treatments or treatment combinations for triple negative breast cancer, b) discover, validate and/or test biomarkers for patient stratification and/or monitoring treatment response, c) identify and elucidate mechanisms and/or predictors of resistance, and/or explore new approaches for overcoming treatment resistance in triple negative disease.

- **Biology of Breast Cancer – Host and/or Tumor Genetics**
  Research seeking to apply knowledge of host and/or tumor genetics to study the biological mechanisms of initiation and progression of breast cancer relevant to prevention and treatment.

- **Disparities in Breast Cancer Outcomes across Population Groups**
  Research seeking to a) understand the biologic, behavioral, and social causes of disparities in breast cancer, and/or b) identify, validate and test health services and public health interventions that address the causes of disparities in care and outcomes across population groups.
FUNDING INFORMATION

Applicants may request either three or four years of funding as follows:

- Up to a total of $750,000 over three years (combined direct and indirect costs); or
- Up to a total of $1,000,000 over four years (combined direct and indirect costs)

Budgets are not required to be equivalent across each year of the Grant, but rather should reflect the costs appropriate to support the research project each year.

Note the following guidelines:

- Personnel on the project are limited to a base salary at or below $250,000 per year
- Equipment costs are limited to no more than 30% of total direct costs
- Indirect costs cannot exceed 25% of total direct costs (including any indirect costs paid through subcontracts or consortia)
- Professional membership dues are not allowed

DESIGNATED RECIPIENTS

Grants will be awarded to a single Principal Investigator (PI) or one PI and one Co-Principal Investigator (Co-PI).

Primary Institution

For grants awarded to a PI/Co-PI team, Grant Agreements will be executed between Susan G. Komen for the Cure and the PI’s institution. The primary institution will serve as the administrator of the grant funds and will hold responsibility for the disbursement of the funds to other participating institutions, management of the budget, and submission of all required documents and reports. It is expected that the primary institution will enter into subcontracts with any other participating institutions, and assurances that these contractual agreements have been executed will be required prior to funding.

Susan G. Komen for the Cure®

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure®, we have invested more than $1.9 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world.
ELIGIBILITY

PIs, Co-PIs, and institutions must conform to the following eligibility criteria to be considered for funding through an IIR Grant. Eligibility requirements must be met at the time of full application submission.

PIs and Co-PIs
• Must have a doctoral degree, including MD, PhD, DrPH, DO, or equivalent
• Must not simultaneously apply for a Komen Career Catalyst Research Grant or be the Principal Investigator (PI) on a Career Catalyst Research Grant currently in the first or second year of funding
• Must ensure that all past and current Komen-funded Grants are up to date and in compliance with all Komen requirements; e.g., progress report submissions, IRB approvals, etc.
• Are not required to be U.S. citizens or residents.

Institutions
• Primary institution must be a nonprofit institution or organization anywhere in the world
• Other participating institutions may be nonprofit institutions or industry partners, however, industry partners may not be reimbursed for any fee or profit
• All institutions and industry partners must agree to adhere to Komen’s Policies and Procedures for Research and Training Grants including, for example, regulatory assurances, ownership of equipment, intellectual property, liability and insurance and reporting requirements. Copies of these Policies and Procedures are available at http://ww5.komen.org/ResearchGrants/FundingOpportunities.html

REVIEW PROCESS

Susan G. Komen for the Cure® utilizes a multi-step approach to application and review that requires submission of a pre-application and submission of a full application upon invitation only. Pre-applications are first administratively reviewed for eligibility, adherence to formatting requirements, and responsiveness to the research focus specified in this RFA. Each qualified application is then reviewed by a panel of three scientists with appropriate expertise and a patient advocate. Scientist and advocate reviewers assess the strengths and weaknesses of each application based on the defined review criteria described below.

Only applicants with pre-applications deemed most meritorious and aligned with Komen’s research mission will be invited to submit full applications. It is anticipated that full applications will be invited from approximately 20-25% of pre-application submitters.

Applicants will be notified of pre-application review decisions via email. Once notifications are sent, applicants will be granted access to un-edited reviewer comments.
Pre-application Scientific Review Criteria
Reviewers will evaluate and score pre-applications based on the following criteria:

<table>
<thead>
<tr>
<th>Research Significance and Clinical Impact</th>
<th>Scientific Approach and Feasibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Will the overarching research question(s), if successfully answered, have significant potential to lead to a reduction in breast cancer incidence and/or mortality within the next decade?</td>
<td>• Will the proposed study hypothesis(es) comprehensively address the overarching research question(s)?</td>
</tr>
<tr>
<td>• If successfully completed, will the research advance our knowledge of breast cancer in an important way and/or contribute to the way that we conduct breast cancer research?</td>
<td>• Will the proposed specific aims fully answer the study hypothesis(es)?</td>
</tr>
<tr>
<td></td>
<td>• Will the scientific approach effectively address each specific aim?</td>
</tr>
<tr>
<td></td>
<td>• Does the research team, as described in their biosketches, contain all of the key expertise that is necessary to successfully address the overarching research question(s)?</td>
</tr>
</tbody>
</table>

PRE-APPLICATION SUBMISSION INSTRUCTIONS
Applications must be submitted online through proposalCENTRAL at https://proposalcentral.altum.com/. Details regarding pre-application formatting, content and supporting documents are provided below. Applicants are encouraged to draft application content using Word or other word-processing software prior to the opening of the application system. Pre-Application Narratives must be converted to PDF prior to submission.

Pre-Application Narrative
Below is a description of the narrative content that must be included in the application, including the recommended page length for each section. Applicants may exceed the recommended page length for a given section provided that the total narrative is no more than 4 pages, including figures and tables. References and biosketches are not included in this page number limit.

Susan G. Komen for the Cure has been dedicated to funding breast cancer research since inception in 1982. At the local level in the U.S., Komen works through a grassroots network of 120 Affiliates who serve as the face and voice of the Komen organization in 48 states across the country. All of the Affiliates actively participate in generating the funds that are used to sponsor the Komen research grants. Twenty five percent of all the money raised locally is pooled at the national level and invested in Research and Training Grants. In 2011, Susan G. Komen for the Cure is funding 82 research grants, totaling $55 million. Of that, over $32 million came directly from the Komen Affiliate Network. More than just numbers, these statistics emphasize that local Komen Affiliates — and through them communities all over the country — are committed to supporting the scientific community at large by raising money and breast cancer awareness.
Research Issue and Clinical Impact and Significance (1 page recommended):
Describe both the research issue that will be addressed in the application and the clinical impact and significance of this issue in terms of incidence and/or mortality reduction. Applicants should address the following points:

• How the proposed research addresses one of the specific annual research foci as described in this RFA
• How the overarching research question(s), if successfully answered, has significant potential to lead to a reduction in breast cancer incidence and/or mortality within the next decade.
• How the outcomes from the proposed research plan will advance our knowledge of breast cancer and/or contribute to changes in the way that research is conducted on this issue.

Hypothesis, Specific Aims and Approach (3 pages recommended):
Clearly and concisely outline the hypothesis(es), specific aims, and the scientific approach that will be taken to address each specific aim. In this section, address the following:

• How the proposed study hypothesis(es) addresses the overarching research question(s).
• How the proposed specific aims will answer the study hypothesis(es).
• How the scientific approach addresses each specific aim.

Pre-Application Supporting Documents
The following documentation is required to support the pre-application:

Biosketches
Required for all key research personnel. Biosketches must be no more than 4 pages each and in NIH format. A template will be available for download on the application website. Applicants are not required to submit a biosketch for advocates, but advocates should be listed as key personnel.

Biosketches are not included in the overall 4-page limit.

References
No more than 10. References are not included in the overall 4-page limit.

Document Format
Please follow the formatting requirements below. Applications not adhering to these format requirements may be administratively withdrawn prior to review.

• Must be in PDF file format.
• Font Size: 12 point or larger.
• Font Type: Times New Roman.
• Spacing: No more than six lines of type within a vertical inch (2.54 cm).
• Page Size: No larger than 8.5 inches x 11.0 inches (21.59 cm x 27.94 cm).
• Margins: At least 0.5 inch (1.27 cm) in all directions.
• Print Area: 7.5 inches x 10.0 inches (19.05 cm x 25.40 cm).
• Use of headers and footers is not permitted.
• Recommended lengths for each narrative section of the application are provided. The complete application narrative must not exceed 4 pages in length.
Guidelines for Images

• Reduce the file size of documents with images by “inserting” the image (as opposed to “cutting” and “pasting”).

• Insert only PNG, GIF or JPG graphic files as images in your Word document. Other graphical file formats are either very large or difficult to manipulate in the document.

• Do not insert Quick Time or TIFF objects into your document.

• Anchor the images you embed in your document. Once you have anchored the “inserted” image, you can format text to wrap around the image.

• Do not edit your images in Word. Use a graphics program.

• Do not embed your images in tables, text boxes, and other form elements.

• Do not add annotations over the images in Word. Add annotations to the images in a graphics program.

FULL APPLICATION SUBMISSION

Only applicants with pre-applications deemed most meritorious and aligned with Komen’s research mission will be invited to submit full applications. Instructions on how to submit a full application will be provided on the pre-application decision date listed above.

QUESTIONS?

Contact information for all inquiries regarding application submission is provided below.

<table>
<thead>
<tr>
<th>Type of Inquiry</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>All programmatic inquiries (including questions related to eligibility, program requirements, Komen policies and procedures, etc.)</td>
<td>Research Programs Help Desk</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:helpdesk@komengrantsaccess.org">helpdesk@komengrantsaccess.org</a></td>
</tr>
<tr>
<td></td>
<td>Phone: 1-866-921-9678 (Toll-free within the United States and Canada)</td>
</tr>
<tr>
<td>All technical inquiries related to the online application system, proposalCENTRAL (including questions related to system access, navigation, document uploads, etc.)</td>
<td>Altum/proposalCENTRAL</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:pcsupport@altum.com">pcsupport@altum.com</a></td>
</tr>
<tr>
<td></td>
<td>Phone: 1-800-875-2562 (Toll-free within the United States and Canada), or 1-703-964-5840 (International)</td>
</tr>
</tbody>
</table>